

GLOBAL PDT LEADER DR COLIN HOPPER JOINS INVION AS CLINICAL ADVISOR

MELBOURNE (AUSTRALIA) 22 June 2026: Invion Limited (ASX: IVX) ("**Invion**" or the "**Company**"), a clinical-stage life sciences company developing its next-generation photodynamic therapy platform (**NGPDT**) called Photosoft™, is pleased to announce the appointment of Dr Colin Hopper, MD FRCS(Ed) FDS RCS, as Clinical Advisor to the Company.

Dr Hopper is one of the world's foremost clinical leaders in photodynamic therapy (**PDT**). He currently serves as President of the International Photodynamic Association (**IPA**), the premier global body for PDT research and clinical advancement.

He also holds senior academic and clinical appointments at University College London (**UCL**), as Associate Clinical Professor Oral and Maxillofacial Surgery at UCL Eastman Dental Institute as well as former Head and Neck Surgeon at UCL Hospitals.

As Clinical Advisor, Dr Hopper will work closely with Invion's scientific and clinical teams to:

- Advise on clinical strategy and indication prioritisation.
- Support protocol development and optimisation for Photosoft-based therapies.
- Provide insights into light delivery techniques, treatment workflows, and patient selection.
- Help guide the translation of Invion's 300+ novel Photosoft compounds across oncology, infectious disease, and other therapeutic areas.

Dr Hopper's career spans more than three decades of pioneering work in PDT across oncology, antimicrobial applications, fluorescence diagnostics, and image-guided interstitial PDT. He has been at the forefront leading one of the world's largest and longest-running portfolio of clinical PDT programs, documenting hundreds of treatments and establishing PDT as a validated therapeutic option for head and neck cancers and other neoplastic conditions.

His contributions to the field have been recognised through the IPA Lifetime Achievement Award in PDT Clinical Research.

Commenting on his appointment to Invion, Dr Hopper said:

"The opportunity to work closely with Invion resonates with my lifetime mission to bring PDT into mainstream clinical practice. Invion's Photosoft provides a compelling next step in this journey, offering a new generation of potentially safer and more efficacious PDT compounds that could reach more patients and indications than ever before."

"I am pleased to join Invion at this pivotal stage and look forward to helping shape the clinical pathways that will bring this technology to patients who stand to benefit most."

Invion's Executive Chair and CEO, Prof Thian Chew, said:

"Dr Hopper's appointment represents a significant strengthening of Invion's clinical and strategic capabilities. His unparalleled clinical experience in PDT will help us"

ASX ANNOUNCEMENT

sharpen our development strategy, identify high-impact indications and ensure our platform technology is optimised for real-world patient care.

"On behalf of the Board, I would like to welcome Dr Hopper. His appointment strengthens our leadership in next-generation PDT and supports our ambition to translate the extensive Photosoft™ platform of proprietary compounds into multiple therapeutic and commercial opportunities."

This announcement was approved for release by Invion's Board of Directors.

Sign up at Invion's Investor Hub to receive regular updates, provide feedback and participate in discussions: <https://investors.inviongroup.com/>

Investor and Media enquiries:

Thian Chew (Chairman & CEO)

T: +61 3 9692 7222

E: investor@inviongroup.com

Brendon Lau (Investor & Media Relations)

M: +61 409 341 613

E: brendon.lau@inviongroup.com

About Invion

Invion is a life-science company leading global research and development of the Photosoft™ technology for the treatment of a range of cancers, atherosclerosis, and infectious diseases. Invion holds the global exclusive license to the Photosoft technology for multiple cancer and non-cancer disease indications. Invion is listed on the ASX (ASX: IVX). Find out more at www.inviongroup.com.

About Next Generation Photodynamic Therapy (NGPDT)

Invion is developing its platform Photosoft™ technology as a novel Next Generation Photodynamic Therapy (NGPDT). NGPDT uses non-toxic photosensitisers and light to selectively kill cancer cells and promote an anti-cancer immune response. Less invasive than surgery and with minimal side effects, NGPDT offers an alternative treatment option aimed at achieving complete tumour regression and long-lasting remission. NGPDT has also demonstrated potential in non-cancer disease areas including broad-spectrum activity across multiple infectious diseases, including bacteria, fungi and viruses. Photosoft has the potential to address the global challenge of antibiotic-resistant "superbugs", in addition to other indications.